2016 Symposium Group photo

Making a Difference

The SSADH community is made up of families, scientists and doctors from around the world working together to make a better life for this very special patient population.

Our Mission

The SSADH Association is a voluntary, not-for-profit, 501(c) (3) organization dedicated to helping children and families affected by an ultra-rare neurometabolic disorder known as Succinic Semialdehyde Dehydrogenase Deficiency or SSADH.

The SSADH Association is committed to those affected with this neurotransmitter disease through education, advocacy and research.

News & Updates

Dried Bloodspots Facilitates SSADH Newborn Detection

August 1, 2019

Gamma-Hydroxybutyrate Content in Dried Bloodspots Facilitates Newborn Detection of Succinic Semialdehyde Dehydrogenase Deficiency. Further, development of a first-tier screening method…

Read More
Phillip L. Pearl, MD

Dr. Pearl Joins NORD Board of Directors

July 23, 2019

Washington, DC, July 19, 2019—The National Organization for Rare Disorders (NORD)®, the leading independent nonprofit organization representing the over 25…

Read More

International Study

May 29, 2019

We have the maximum number of patients that we need to visit Boston Children’s Hospital for the Natural History Study. …

Read More

Natural History Study Starting

March 11, 2019

Sam kicked off the SSADH Natural History Study at Boston Children’s Hospital on March 6, 2019.  We found the study…

Read More

The research team of Drs. Gibson and Roullet makes the news in the WSU Insider.  An article titled, Worldwide Rare Disease Study Led by WSU Researchers, by Judith Van Dongen, WSU Spokane Office of Research, talks about the grant received from the National Institute of Child Health and Human Development to conduct a natural history study for SSADH patients.

The article details the importance of the natural history study and explains how it will help the scientists identify specific biomarkers of disease severity and better predict the natural course of SSADH. Additionally, the article talks about the importance of the natural history study and explains how it will meet prerequisites for FDA approval of new drugs or existing drugs indicated for other conditions.

Click here to read the entire story.

Mike Gibson, far left, and Jean‑Baptiste Roullet (blue sweater) and their team of researchers in the WSU College of Pharmacy and Pharmaceutical Sciences.
(Photo by Cori Kogan, WSU Spokane)

For more information or to enroll in the study please email:
Study Coordinator:  Dr. Melissa DiBacco by email at: Melissa.Dibacco@childrens.harvard.edu
Study Coordinator:  Dr. Kathrin Jeltsch by email at: Kathrin.Jeltsch@med.uni-heidelberg.de


WSU Team Picture